Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.54 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19815803 | 1.00 | APLNR (0.63) | APLNRLMNATSHRCYP3A4GABRA1 | |
| Hydrochloric Acid SCHEMBL28303066 | 0.98 | APLNR (0.61) | APLNRLMNATSHRCYP3A4GABRA1 | |
| SCHEMBL25873254 | 0.91 | APLNR (0.53) | APLNRLMNATSHRCYP3A4GABRA1 | |
| SCHEMBL3101278 | 0.86 | — | — | |
| SCHEMBL1546863 | 0.77 | APLNR (1.00) | APLNRLMNATSHRCYP3A4GABRA1 | |
| SCHEMBL18254434 | 0.77 | APLNR (1.00) | APLNRLMNATSHRCYP3A4GABRA1 | |
| SCHEMBL18254435 | 0.77 | APLNR (1.00) | APLNRLMNATSHRCYP3A4GABRA1 | |
| SCHEMBL19975528 | 0.77 | APLNR (0.63) | APLNRLMNATSHRCYP3A4GABRA1 | |
| SCHEMBL19565582 | 0.77 | APLNR (0.63) | APLNRLMNATSHRCYP3A4GABRA1 | |
| SCHEMBL6398719 | 0.77 | APLNR (0.63) | APLNRLMNATSHRCYP3A4GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193166-A1 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-07-07 | — | — | US | claimed |
| US-20100184707-A1 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-07-22 | — | — | US | claimed |
| US-11998602-B2 | Methods for promoting myelination and for treating demyelinating diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-06-04 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230246229-A1 | ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES | Octet Scientific, Inc. | 2023-08-03 | — | — | US | disclosed |
| WO-2023141301-A1 | ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES | Octet Scientific, Inc. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2021107122-A1 | HYPOXIA RESPONSE CONTROL BY SPECIFIC AMINO ACID OR AMINO ACID-LIKE SUBSTANCE | 学校法人慶應義塾 | 2021-06-03 | — | — | WO | disclosed |
| US-20210023218-A1 | METHODS FOR PROMOTING MYELINATION AND FOR TREATING DEMYELINATING DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-28 | — | — | US | disclosed |
| WO-2019172969-A1 | METHODS FOR PROMOTING MYELINATION AND FOR TREATING DEMYELINATING DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20190112656-A1 | MITOCHONDRIAL BIOMARKER REFLECTING AGING | KAWASAKI GAKUEN EDUCATIONAL FOUNDATION (JP) | 2019-04-18 | — | — | US | disclosed |
| US-20160206579-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-07-21 | — | — | US | disclosed |
| US-20160193166-A1 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-07-07 | — | — | US | disclosed |
| US-20120027723-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-02-02 | — | — | US | disclosed |
| EP-2393490-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089355-A1 | TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-08-12 | — | — | WO | disclosed |
| EP-0666843-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFAMIC ACIDS USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0428831-B1 | Process of preparation of pyridine-3-sulfonic acids | RUETGERSWERKE AG (DE) | 1994-06-08 | — | — | EP | disclosed |
| US-5082944-A | Production of pyridine-3-sulfonic acid | RUTGERSWERKE AG (DE) | 1992-01-21 | — | — | US | disclosed |
| EP-0428831-A1 | Process of preparation of pyridine-3-sulfonic acids | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | APLNR 3372/4885LMNA 1681/4885TSHR 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.